Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1989 1
1995 1
2000 1
2004 1
2005 2
2008 1
2015 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Tovele
Page 1
Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy.
Cassileth PA, Lusk EJ, Torri S, DiNubile N, Gerson SL. Cassileth PA, et al. Among authors: gerson sl. Arch Intern Med. 1983 Jul;143(7):1347-9. Arch Intern Med. 1983. PMID: 6347109 Clinical Trial.
No GI intolerance to chemotherapy was noted in 24 (83%) of the 29 dexamethasone trials v 16 (57%) of the 28 placebo trials. Dexamethasone trials produced the following results: no side effects in 50% (14/29), insomnia the night after chemotherapy in 21% (6/29), an increase …
No GI intolerance to chemotherapy was noted in 24 (83%) of the 29 dexamethasone trials v 16 (57%) of the 28 placebo trials. Dexametha …
Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study.
Gururangan S, Turner CD, Stewart CF, O'Shaughnessy M, Kocak M, Poussaint TY, Phillips PC, Goldman S, Packer R, Pollack IF, Blaney SM, Karsten V, Gerson SL, Boyett JM, Friedman HS, Kun LE. Gururangan S, et al. Among authors: gerson sl. Clin Cancer Res. 2008 Feb 15;14(4):1124-30. doi: 10.1158/1078-0432.CCR-07-4242. Clin Cancer Res. 2008. PMID: 18281546 Clinical Trial.
PURPOSE: VNP40101M (Cloretazine), a novel DNA alkylating agent, was evaluated in a phase I study in children with recurrent brain tumors. EXPERIMENTAL DESIGN: VNP40101M was given i.v. daily for 5 consecutive days every 6 weeks for up to eight cycles. ...
PURPOSE: VNP40101M (Cloretazine), a novel DNA alkylating agent, was evaluated in a phase I study in children with recurrent brain tumors. EX …
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Hammond LA, Eckardt JR, Kuhn JG, Gerson SL, Johnson T, Smith L, Drengler RL, Campbell E, Weiss GR, Von Hoff DD, Rowinsky EK. Hammond LA, et al. Among authors: gerson sl. Clin Cancer Res. 2004 Mar 1;10(5):1645-56. doi: 10.1158/1078-0432.ccr-03-0174. Clin Cancer Res. 2004. PMID: 15014015 Clinical Trial.
EXPERIMENTAL DESIGN: Sixty-three patients were randomized to receive treatment with oral TEM daily on days 1-5 and BCNU administered i.v., either on day 1 before TEM [Sequence (Seq) B-->T] or day 5 after TEM (Seq T-->B). ...
EXPERIMENTAL DESIGN: Sixty-three patients were randomized to receive treatment with oral TEM daily on days 1-5 and BCNU administered i.v …
CD34+ selection of hematopoietic blood cell collections and autotransplantation in lymphoma: overnight storage of cells at 4 degrees C does not affect outcome.
Lazarus HM, Pecora AL, Shea TC, Koç ON, White JM, Gabriel DA, Cooper BW, Gerson SL, Krieger M, Sing AP. Lazarus HM, et al. Among authors: gerson sl. Bone Marrow Transplant. 2000 Mar;25(5):559-66. doi: 10.1038/sj.bmt.1702175. Bone Marrow Transplant. 2000. PMID: 10713636 Clinical Trial.
Lymphoma patients underwent PBPC mobilization with cyclophosphamide 4 g/m2 i.v. and G-CSF 10 microg/kg/day subcutaneously. Patients were prospectively randomized to have each PBPC collection enriched for CD34+ cells with the CellPro CEPRATE SC System either immediately or …
Lymphoma patients underwent PBPC mobilization with cyclophosphamide 4 g/m2 i.v. and G-CSF 10 microg/kg/day subcutaneously. Patients w …
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Giles F, et al. Among authors: gerson s. Clin Cancer Res. 2005 Nov 1;11(21):7817-24. doi: 10.1158/1078-0432.CCR-05-1070. Clin Cancer Res. 2005. PMID: 16278404 Clinical Trial.
A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease. DESIGN: Ara-C was given i.v. at a fixed dose of 1.5 gm/m(2)/d by continuous infusion for 4 days (patients ages <65 years …
A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory …
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
Gajewski TF, Sosman J, Gerson SL, Liu L, Dolan E, Lin S, Vokes EE. Gajewski TF, et al. Among authors: gerson sl. Clin Cancer Res. 2005 Nov 1;11(21):7861-5. doi: 10.1158/1078-0432.CCR-05-0060. Clin Cancer Res. 2005. PMID: 16278409 Clinical Trial.
They were accrued into two cohorts based on prior chemotherapy. O(6)BG (120 mg/m(2)) was administered i.v. followed by BCNU (40 mg/m(2)) on an outpatient basis. Peripheral blood mononuclear cells (PBMC) were collected pre- and 18 hours post-O(6)BG to analyze AGT depletion. …
They were accrued into two cohorts based on prior chemotherapy. O(6)BG (120 mg/m(2)) was administered i.v. followed by BCNU (40 mg/m( …
Modulation of O6-alkylguanine-DNA alkyltransferase in rats following intravenous administration of O6-methylguanine.
Dexter EU, Yamashita TS, Donovan C, Gerson SL. Dexter EU, et al. Among authors: gerson sl. Cancer Res. 1989 Jul 1;49(13):3520-4. Cancer Res. 1989. PMID: 2731174
The pharmacokinetics of O6-methylguanine were evaluated in female Sprague-Dawley rats following administration of a single 40 mg/kg i.v. bolus dose. Two-compartment pharmacokinetic analysis revealed a terminal elimination half-life of 2.3 +/- 0.68 h, a total body clearance …
The pharmacokinetics of O6-methylguanine were evaluated in female Sprague-Dawley rats following administration of a single 40 mg/kg i.v …
Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate.
Berg SL, Gerson SL, Godwin K, Cole DE, Liu L, Balis FM. Berg SL, et al. Among authors: gerson sl. Cancer Res. 1995 Oct 15;55(20):4606-10. Cancer Res. 1995. PMID: 7553637
The plasma and cerebrospinal fluid (CSF) pharmacokinetics of O6BG and its active metabolite, O6-benzyl-8-oxoguanine, were studied in a nonhuman primate model after 200 mg/m2 had been injected i.v. The parent drug and the metabolite were measured with a reverse-phase HPLC a …
The plasma and cerebrospinal fluid (CSF) pharmacokinetics of O6BG and its active metabolite, O6-benzyl-8-oxoguanine, were studied in a nonhu …